The Biden-Harris administration, through the U.S. National Institutes of Health, has licensed 11 COVID-19 research tools and early-stage vaccine and diagnostic candidates to the Medicines Patent Pool, according to a Department of Health & Human Services announcement Thursday.
The licenses, which includes the SARS-CoV-2 stabilized spike protein, will allow manufacturers around the world to work with MPP and the World Health Organization’s COVID-19 Technology Access Pool to develop vaccines, treatments, and diagnostics for people in low- and middle-income countries, the department said.
This story was produced by Bloomberg Law Automation.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.